Scoping review maps thin evidence base for thymosin alpha-1 in cancer care

The wire

1. 01The review in Pharmaceuticals found thymosin alpha-1 used mainly as a subcutaneous adjunct at 1.6 mg alongside chemotherapy, radiotherapy, targeted therapy or checkpoint inhibitors in hepatobiliary, thoracic and gastrointestinal cancers.
2. 02Clinicians asked about thymalfasin as an immunomodulatory add-on now have a mapped picture of where evidence exists and where it does not.
3. 03Heterogeneity limited comparability, safety reporting was inconsistent, and one case described severe multisystem immune-related toxicity during combination treatment without established causality; the authors call for prospective controlled trials.

From the source

Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review

Pharmaceuticals (Basel, Switzerland) · 2026 Sep 19 · Kim SD, Kim KR, Kim DH et al.